

STAT Inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/SCAFDB29A89EN.html>

Date: January 2022

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: SCAFDB29A89EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "STAT Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

STAT Inhibitors Understanding

STAT Inhibitors: Overview

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides.

STAT Inhibitors Emerging Drugs Chapters

This segment of the STAT Inhibitors report encloses its detailed analysis of various

drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

STAT Inhibitors Emerging Drugs

SHR0302: Jiangsu Hengrui Medicine

SHR0302 is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. It inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has an anti-proliferative and anti-inflammatory effect. It is currently in phase III stage of development.

OPB-111077: Otsuka Pharmaceutica

OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy.

Niclosamide intramuscular depot: Daewoong Pharmaceutical

Niclosamide intramuscular depot is being developed by Daewoong Pharmaceutical for the treatment of COVID 2019 infections. It is currently in phase I stage of development.

Further product details are provided in the report.....

STAT Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in STAT Inhibitors

There are approx. 60+ key companies which are developing the therapies based on STAT Inhibitors. The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e. phase II/III include Jiangsu Hengrui Medicine and others

Phases

DelveInsight's report covers around 60+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

STAT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

STAT Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Reistone's oral JAK1 inhibitor, SHR0302, is a China developed molecule licensed-in from Jiangsu Hengrui Medicine Co Ltd (Hengrui).

STAT Inhibitors Report Insights

STAT Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

STAT Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

What are the current treatment options available based on the STAT Inhibitors?

How many companies are developing therapies by working on STAT Inhibitors?

What are the principal therapies developed by these companies in the industry?

How many therapies are developed by each company for STAT Inhibitors to treat disease condition?

How many emerging therapies are in early-stage, mid-stage, and late stage of development for STAT Inhibitors?

Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the STAT Inhibitors therapies?

Which are the dormant and discontinued products and the reasons for the same?

What is the unmet need for current therapies developed based on this mechanism of action?

What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for STAT Inhibitors and their status?

What are the results of the clinical studies and their safety and efficacy?

What are the key designations that have been granted for the emerging therapies for STAT Inhibitors?

How many patents are granted and pending for the emerging therapies of STAT Inhibitors?

Key Players

Singh Biotechnology

AndroScience Corporation

Wyeth

Astellas

Dolthera

Jiangsu Hengrui Medicine

Otsuka Pharmaceutica

Daewoong Pharmaceutical

Key Products

SBT 101

ASC ST.Z1

Research programme: STAT3 transcription factor inhibitors

Research programme: STAT6 inhibitors

AVT 02

SHR0302

OPB-111077

Niclosamide intramuscular depot

Contents

Introduction

Executive Summary

STAT Inhibitors: Overview

Classification

Mechanism of Action

Structure

Application

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

STAT Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

STAT Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

STAT Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SHR0302: Jiangsu Hengrui Medicine

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

OPB-111077: Otsuka Pharmaceutica

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Niclosamide intramuscular depot: Daewoong Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Inactive Products

Comparative Analysis

STAT Inhibitors Key Companies

STAT Inhibitors Key Products

STAT Inhibitors- Unmet Needs

STAT Inhibitors- Market Drivers and Barriers

STAT Inhibitors- Future Perspectives and Conclusion

STAT Inhibitors Analyst Views

STAT Inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for STAT Inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for STAT Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: STAT Inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/SCAFDB29A89EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SCAFDB29A89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970